Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

By Christy Santhosh May 13 (Reuters) - U.S. Food and Drug Administration Commissioner Dr. Marty Makary's departure comes as a ...

Biotech stocks tied to cancer, autoimmune and rare disease therapies gain attention as M&A activity boosts sector sentiment.

Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, ...

Inovio Pharmaceuticals and Novavax stocks pare back earlier gains as the rally loses enthusiasm. Following a robust rally, Moderna appears to be regaining leadership within the biotech space. This ...

The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech ...

Legend Biotech Corp LEGN reported downbeat results for the first quarter on Tuesday. The company posted quarterly losses of 3 ...

CBSET plans to build a 110K SF life sciences facility in Waltham, the Boston Business Journal first reported. The new ...

Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...

This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S.